



Leading the Life-Sciences Industry in the Fight Against AMR

The AMR Industry Alliance is a coalition of life-sciences industry companies & associations established to provide sustainable solutions to combat antimicrobial resistance (AMR). The Alliance includes over 100 biotech, diagnostics, generics, and research-based pharmaceutical companies & associations.

- ▶ In the absence of a comprehensive effort, infections with multi-drug-resistant organisms are predicted to be the **leading cause of death worldwide by 2050.**
- ▶ WHO has declared that AMR is one of the **top 10 global public health threats** facing humanity.
- ▶ According to the Lancet, antimicrobial-resistant bacteria may have **directly accounted for 1.27 million deaths** in 2019.

The AMR Industry Alliance harnesses, measures and drives the power of the life science industry to curb AMR across four focus areas:

RESEARCH & SCIENCE to meet public health needs with new innovative diagnostics and treatments



APPROPRIATE USE of antibiotics to reduce the development of AMR with the support of vaccines and diagnostics



ACCESS to quality antibiotics and ensuring new ones are available to all, and improve and accelerate access to diagnostics in low- and middle-income countries



MANUFACTURING to mitigate environmental impact and advance responsible manufacturing through standard setting



DIAGNOSTICS



GENERICS



R&D PHARMA



BIOTECHS



INSPIRING ACTION: THE IMPACT OF AND RECOMMENDATIONS ON INCLUDING DIAGNOSTICS IN NATIONAL ACTION PLANS

This report examines the role of diagnostics in national action plans (NAPs) and highlights successful examples of integrating and implementing diagnostics into NAPs in LMICs to combat AMR. Diagnostics form the basis of good stewardship and should be included in any national action plan. The report provides recommendations to policymakers on leveraging non-governmental sectors, real-world experience, and further investment in diagnostics for successful NAP implementation.



EQUITABLE AND RESPONSIBLE ACCESS ROADMAP

The Equitable & Responsible Access Roadmap highlights key barriers to diagnostics and antimicrobial access – and outlines solutions to tackle these barriers, including diagnostics infrastructure, recognition of the value of diagnostic technology, antibiotic regulatory issues, forecasting and surveillance, and antibiotic procurement challenges. The Roadmap consists of a detailed report and illustrative infographic.

LEAVING THE LAB: TRACKING THE DECLINE IN AMR R&D PROFESSIONALS

This report identifies an exodus of scientific researchers with expertise in antimicrobials as a growing barrier to developing the new antibiotics needed to tackle the rise in antimicrobial resistance, with just 3,000 active researchers focused on developing new antibiotics globally. The report examines the impact that underinvestment in antimicrobial research is having on the retention of scientists.



CALL-TO-ACTION IN THE FIGHT AGAINST AMR

AMR Industry Alliance and its members, stakeholders in the public and private sectors, and other friends of the Alliance launched a formal call-to-action in the lead-up to the United Nations' High-level Meeting on AMR for Member States, addressing responsible manufacturing, the R&D ecosystem, barriers to equitable access, and appropriate use of antimicrobials.

